Understanding UGT3A1: A Potential Drug Target and Biomarker (G133688)

Target Name: UGT3A1

NCBI ID: G133688

UGT3A1

Understanding UGT3A1: A Potential Drug Target and Biomarker

UGT3A1 (UD3A1_HUMAN), a gene that encodes the UGT3A1 enzyme, is a potential drug target and biomarker for various diseases. The UGT3A1 enzyme is a member of the UGT family, which is involved in the detoxification of a wide variety of drugs, including many drugs that are used to treat human diseases.

The UGT3A1 gene has been shown to be involved in the metabolism of a variety of drugs, including many anti-cancer drugs, which are often administered to cancer patients. One of the primary mechanisms by which UGT3A1 is involved in drug metabolism is through its role in the metabolism of drug metabolites, which are formed when the parent drug is broken down by the liver into its active metabolite.

Studies have shown that UGT3A1 is a critical enzyme in the metabolism of many drugs, including the chemotherapy drug irinotecan. In irinotecan, which is used to treat various cancers, UGT3A1 is shown to be a major metabolite of the drug, with studies showing that it is formed from the original drug at a rate of up to 90%.

In addition to its role in drug metabolism, UGT3A1 is also involved in the detoxification of other substances that are harmful to the body. For example, UGT3A1 is shown to be involved in the detoxification of the neurotoxin cadmium, which is commonly found in environmental pollutants and has been linked to a variety of neurological disorders.

Despite its potential as a drug target and biomarker, UGT3A1 is not yet widely studied. There are currently few studies that have directly investigated the role of UGT3A1 in drug metabolism or disease, and more research is needed to fully understand its potential as a drug target and biomarker.

In conclusion, UGT3A1 (UD3A1_HUMAN) is a gene that encodes an enzyme that is involved in the detoxification of drugs and other substances that are harmful to the body. Its potential as a drug target and biomarker is currently being investigated, and more research is needed to fully understand its role in the development and treatment of various diseases.

Protein Name: UDP Glycosyltransferase Family 3 Member A1

Functions: UDP-glucuronosyltransferases catalyze phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase water solubility and enhance excretion. They are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds (By similarity)

The "UGT3A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT3A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets